How does albuterol compare to erythromycin in treating acute bronchitis. What are the effects of albuterol on cough symptoms in acute bronchitis patients. Is albuterol more effective than antibiotics for acute bronchitis relief. How do smokers and nonsmokers respond to albuterol treatment for acute bronchitis. What are the side effects of albuterol compared to erythromycin in acute bronchitis treatment.

Understanding Acute Bronchitis and Treatment Options

Acute bronchitis is a common respiratory condition characterized by inflammation of the bronchial tubes, often resulting in a persistent cough. Traditional treatment approaches have included antibiotics, but recent research suggests that bronchodilators like albuterol may offer an effective alternative. This article explores a comparative study between albuterol and erythromycin for the treatment of acute bronchitis, shedding light on their efficacy and potential benefits.

What is Acute Bronchitis?

Acute bronchitis is a respiratory infection that causes inflammation in the bronchial tubes, leading to symptoms such as coughing, wheezing, and chest discomfort. It typically lasts for a few weeks and can be caused by viral or bacterial infections. The condition often resembles asthma in terms of pulmonary function test results, which has led researchers to explore bronchodilators as a potential treatment option.

The Rationale Behind Using Albuterol for Acute Bronchitis

Albuterol, a bronchodilator commonly used in asthma treatment, has gained attention as a potential therapy for acute bronchitis. The reasoning behind this approach stems from the observation that pulmonary function tests in acute bronchitis patients often mirror those of asthma patients. This similarity suggests that bronchodilators might effectively alleviate symptoms associated with acute bronchitis.

How Does Albuterol Work?

Albuterol is a short-acting beta-2 agonist that works by relaxing the smooth muscles in the airways. This action helps to open up the bronchial tubes, making breathing easier and potentially reducing cough symptoms. By addressing the underlying bronchial constriction, albuterol may offer relief to acute bronchitis patients experiencing breathing difficulties and persistent coughing.

Study Design: Comparing Albuterol and Erythromycin

To evaluate the effectiveness of albuterol in treating acute bronchitis, a prospective, randomized, double-blinded study was conducted. The research compared the efficacy of albuterol against erythromycin, an antibiotic commonly prescribed for respiratory infections. This rigorous study design aimed to provide objective insights into the relative merits of these two treatment approaches.

Participant Selection and Methodology

The study included patients who presented to family physicians with specific criteria:

• A productive cough lasting less than 30 days
• No history or evidence of pneumonia
• Absence of other pulmonary or cardiac diseases

Participants were randomly assigned to receive either albuterol or erythromycin. They were asked to complete a 7-day symptom diary and return for a follow-up examination after one week of treatment. This methodology allowed for a comprehensive assessment of symptom progression and overall patient well-being throughout the treatment period.

Key Findings: Albuterol’s Impact on Cough Symptoms

The study revealed significant differences in cough resolution between the albuterol and erythromycin groups. After 7 days of treatment, patients treated with albuterol were less likely to be coughing compared to those treated with erythromycin. The difference was statistically significant, with only 41% of albuterol-treated patients still coughing after a week, compared to 88% in the erythromycin group.

Efficacy Across Different Patient Groups

Interestingly, the positive effects of albuterol were observed across various patient subgroups:

1. Smokers and nonsmokers both showed improved outcomes with albuterol treatment.
2. Patients with purulent-appearing sputum also benefited from albuterol therapy.

These findings suggest that albuterol’s efficacy in treating acute bronchitis is not limited to specific patient populations, making it a potentially versatile treatment option.

Additional Benefits and Trends Observed with Albuterol Treatment

Beyond the primary outcome of cough resolution, the study identified several other trends favoring albuterol treatment:

• Earlier improvement in cough symptoms
• Enhanced overall feeling of well-being

These observations, while not reaching statistical significance, indicate that albuterol may offer broader benefits to patients suffering from acute bronchitis. The potential for quicker symptom relief and improved quality of life during the illness could be significant advantages for patients seeking rapid recovery.

Are There Any Drawbacks to Albuterol Treatment?

Despite the positive outcomes associated with albuterol, the study found no significant differences between the treatment groups in several areas:

• Time taken to return to work
• Duration until resumption of normal activities
• Overall improvement in patient well-being

Additionally, minor side effects were reported equally in both the albuterol and erythromycin groups. This suggests that while albuterol may offer superior cough relief, it does not necessarily accelerate overall recovery or reduce the likelihood of experiencing minor adverse effects.

Implications for Antibiotic Use in Acute Bronchitis

The study’s findings have important implications for the use of antibiotics in treating acute bronchitis. With albuterol showing greater efficacy in symptom relief, particularly in cough resolution, there may be a case for reconsidering the routine prescription of antibiotics like erythromycin for this condition. This is especially relevant given the growing concerns about antibiotic resistance and the need for more targeted use of these medications.

Challenging Traditional Treatment Approaches

The superior performance of albuterol in this study challenges the traditional approach of prescribing antibiotics for acute bronchitis. It suggests that targeting the bronchial constriction and associated symptoms with a bronchodilator may be more effective than attempting to address a potential bacterial infection that may not be present in all cases. This shift in treatment paradigm could lead to more tailored and effective management of acute bronchitis cases.

Future Directions and Research Opportunities

While this study provides valuable insights into the potential of albuterol as a treatment for acute bronchitis, it also opens up several avenues for future research:

1. Long-term follow-up studies to assess the durability of treatment effects
2. Investigations into the optimal dosing and duration of albuterol therapy for acute bronchitis
3. Exploration of combination therapies that may enhance the benefits of bronchodilator treatment
4. Comparative studies with other bronchodilators or treatment modalities

These research directions could further refine our understanding of how to best manage acute bronchitis and improve patient outcomes.

Potential for Personalized Treatment Approaches

The study’s findings also highlight the potential for more personalized treatment approaches in acute bronchitis. Given that both smokers and nonsmokers, as well as patients with purulent sputum, benefited from albuterol treatment, future research could explore whether certain patient characteristics or biomarkers might predict an even better response to bronchodilator therapy. This could lead to more targeted and effective treatment strategies tailored to individual patient profiles.

Clinical Implications and Recommendations

Based on the study’s results, healthcare providers may want to consider albuterol as a first-line treatment option for patients presenting with acute bronchitis. The potential for faster symptom relief, particularly in terms of cough resolution, makes it an attractive alternative to antibiotics. However, it’s important to note that treatment decisions should always be made on a case-by-case basis, taking into account the patient’s overall health status, medical history, and the severity of their symptoms.

Implementing Albuterol Treatment in Clinical Practice

For clinicians considering incorporating albuterol into their treatment protocols for acute bronchitis, several factors should be considered:

• Patient education on proper use of albuterol inhalers or nebulizers
• Monitoring for potential side effects, although these appear to be minimal based on the study
• Follow-up assessments to ensure symptom improvement and address any concerns
• Consideration of individual patient factors that might influence treatment response

By carefully implementing albuterol treatment and monitoring patient responses, healthcare providers can optimize the management of acute bronchitis cases and potentially improve patient outcomes.

In conclusion, this comparative study between albuterol and erythromycin for the treatment of acute bronchitis provides compelling evidence for the efficacy of bronchodilator therapy in managing this common respiratory condition. The superior cough resolution and potential for earlier symptom improvement associated with albuterol treatment suggest that it may be a more effective option than commonly used antibiotics. As research in this area continues to evolve, healthcare providers and patients alike may benefit from reconsidering traditional treatment approaches and exploring the potential of targeted bronchodilator therapy for acute bronchitis.

A comparison of albuterol and erythromycin for the treatment of acute bronchitis

Save citation to file

Format:

Summary (text)PubMedPMIDAbstract (text)CSV

Add to Collections

• Create a new collection
• Add to an existing collection

Name your collection:

Name must be less than 100 characters

Choose a collection:

Unable to load your collection due to an error
Please try again

Add to My Bibliography

• My Bibliography

Unable to load your delegates due to an error
Please try again

Your saved search

Name of saved search:

Search terms:

Test search terms

Email:

(change)

Which day?

The first SundayThe first MondayThe first TuesdayThe first WednesdayThe first ThursdayThe first FridayThe first SaturdayThe first dayThe first weekday

Which day?

SundayMondayTuesdayWednesdayThursdayFridaySaturday

Report format:

SummarySummary (text)AbstractAbstract (text)PubMed

Send at most:

1 item5 items10 items20 items50 items100 items200 items

Send even when there aren’t any new results

Optional text in email:

Create a file for external citation management software

Clinical Trial

. 1991 Nov;33(5):476-80.

W J Hueston 
¹

Affiliations

Affiliation

• ¹ Primary Care Division, St Claire Medical Center, Morehead, Kentucky.

• PMID:

  1940815

Clinical Trial

W J Hueston.

J Fam Pract.

1991 Nov.

. 1991 Nov;33(5):476-80.

Author

W J Hueston 
¹

Affiliation

• ¹ Primary Care Division, St Claire Medical Center, Morehead, Kentucky.

• PMID:

  1940815

Abstract

Background:

Based on observations that pulmonary function tests of patients with acute bronchitis resemble those of patients with asthma, it was hypothesized that a bronchodilator may be an effective form of treatment for patients with acute bronchitis.

Methods:

Albuterol was compared with erythromycin in a prospective, randomized, double-blinded fashion. Participants were patients who presented to family physicians with a history of having a productive cough of less than 30 days’ duration, no history or evidence of pneumonia, and no other pulmonary or cardiac disease. Patients completed a 7-day symptom diary and returned to their physician after 1 week of therapy for reexamination.

Results:

Patients treated with albuterol were less likely to be coughing after 7 days of treatment than patients treated with erythromycin (41% vs 88%, P less than .05). This was true for both smokers and nonsmokers and in patients with purulent-appearing sputum. Trends toward an earlier improvement in cough and an improved feeling of well-being also were observed in the albuterol group. No differences between groups were found as to the length of time before patients returned to work, the length of time until patients resumed normal activities, or the overall improvement in patient well-being. Minor side effects were equal in both groups.

Conclusions:

Oral albuterol may be more effective than commonly used antibiotics in relieving the symptoms of acute bronchitis.

Similar articles

• Albuterol delivered by metered-dose inhaler to treat acute bronchitis.

  Hueston WJ.

  Hueston WJ.
  J Fam Pract. 1994 Nov;39(5):437-40.
  J Fam Pract. 1994.

  PMID: 7864949

  Clinical Trial.

• A placebo-controlled, double-blind trial of erythromycin in adults with acute bronchitis.

  Dunlay J, Reinhardt R, Roi LD.

  Dunlay J, et al.
  J Fam Pract. 1987 Aug;25(2):137-41.
  J Fam Pract. 1987.

  PMID: 3302093

  Clinical Trial.

• A randomized controlled trial of oral albuterol in acute cough.

  Littenberg B, Wheeler M, Smith DS.

  Littenberg B, et al.
  J Fam Pract. 1996 Jan;42(1):49-53.
  J Fam Pract. 1996.

  PMID: 8537805

  Clinical Trial.

• Antibiotic treatment of acute bronchitis in smokers: a systematic review.

  Linder JA, Sim I.

  Linder JA, et al.
  J Gen Intern Med. 2002 Mar;17(3):230-4. doi: 10.1046/j.1525-1497.2002.10405.x.
  J Gen Intern Med. 2002.

  PMID: 11929510
  Free PMC article.

  Review.

• Treatment of acute bronchitis in adults without underlying lung disease.

  MacKay DN.

  MacKay DN.
  J Gen Intern Med. 1996 Sep;11(9):557-62. doi: 10.1007/BF02599608.
  J Gen Intern Med. 1996.

  PMID: 8905509
  Free PMC article.

  Review.

See all similar articles

Cited by

• Macrolides versus placebo for chronic asthma.

  Undela K, Goldsmith L, Kew KM, Ferrara G.

  Undela K, et al.
  Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD002997. doi: 10.1002/14651858.CD002997.pub5.
  Cochrane Database Syst Rev. 2021.

  PMID: 34807989
  Free PMC article.

  Review.

• Effects of Oral Procaterol for Postinfectious Cough in Adults: Single-Centre, Randomized Double-Blind, Placebo-Controlled Trial.

  Pornsuriyasak P, Rattanasiri S, Unwanatham N, Kawamatawong T, Jankum P, Thakkinstian A.

  Pornsuriyasak P, et al.
  Korean J Fam Med. 2021 Mar;42(2):159-165. doi: 10.4082/kjfm.19.0118. Epub 2020 May 14.
  Korean J Fam Med. 2021.

  PMID: 32403902
  Free PMC article.

• Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis.

  Becker LA, Hom J, Villasis-Keever M, van der Wouden JC.

  Becker LA, et al.
  Cochrane Database Syst Rev. 2015 Sep 3;2015(9):CD001726. doi: 10.1002/14651858.CD001726.pub5.
  Cochrane Database Syst Rev. 2015.

  PMID: 26333656
  Free PMC article.

  Review.

• Bronchitis (acute).

  Wark P.

  Wark P.
  BMJ Clin Evid. 2011 Jun 20;2011:1508.
  BMJ Clin Evid. 2011.

  PMID: 21711957
  Free PMC article.

  Review.

• Bronchitis (acute).

  Wark P.

  Wark P.
  BMJ Clin Evid. 2008 Jul 17;2008:1508.
  BMJ Clin Evid. 2008.

  PMID: 19445737
  Free PMC article.

  Review.

See all “Cited by” articles

Publication types

MeSH terms

Substances

Cite

Format:

AMA

APA

MLA

NLM

Send To

Types of Inhalers and Nebulizers

Just when you think you’ve gotten over that respiratory infection, bronchitis hits. The coughing, chest soreness, and fatigue can really get you down.

While acute bronchitis will usually go away without prescription treatments, chronic or an especially nasty case of acute bronchitis may require some extra help.

We explain inhaled treatments for bronchitis, including nebulizer and inhaler treatments, and how they may help.

Inhalers are medications that are delivered through the mouth and to the lungs.

Usually this is a device with a short mouthpiece that connects to a small canister you press down on. When you press down and inhale, the medication enters your mouth and goes down into your lungs.

A doctor may prescribe a few different types of inhaler medications for bronchitis. These include the following:

Beta-2 agonists

Some of the most common inhaler medications are short-acting beta-2 agonists. These include medications like albuterol and salbutamol.

Doctors prescribe beta-2 agonists to treat:

• asthma
• chronic obstructive pulmonary disease (COPD)
• severe coughing that can come with acute bronchitis

These medications work by relaxing airway passages in the lungs, which can make it easier to breathe.

The Cochrane Database of Systematic Reviews analyzed the results of five different studies of beta-2 agonists as a treatment for acute bronchitis in adults.

They concluded that there’s little evidence to support the use of beta-2 agonists in adults with acute bronchitis.

However, they did find that inhalers helped people who tended to wheeze frequently, even when they weren’t sick.

Inhaled corticosteroids

Inhaled corticosteroids help to reduce airway inflammation. This can be helpful when you have bronchitis, because it’s usually after an upper respiratory infection and your lungs are already very irritated.

These medications won’t relieve a wheezing attack immediately, but they can help to reduce:

• airway swelling
• excess mucus
• tight airways

Examples of inhaled corticosteroids doctors prescribe include:

• beclomethasone
• budesonide
• fluticasone

Long-acting beta-2 agonists (LABAs)

These medications are similar to short-acting beta-2 agonists like albuterol. They aren’t meant for acute attacks of wheezing, but rather reduce the risk of wheezing all day.

Examples of LABAs include arformoterol tartrate (Brovana) and formoterol fumarate (Oxeze, Foradil).

Doctors usually prescribe these with inhaled corticosteroids.

Nebulizer treatments are another form of inhaled medications. Instead of a short mouthpiece, nebulizer treatments usually have a longer mouthpiece and an air compressor that helps convert the medication to a fine mist.

Doctors often prescribe nebulizers to children who may have a harder time using an inhaler properly.

Instead of having to time the pumps to breathe medication in, a person just takes deep breaths in and out to take in the medication.

Nebulizers are also useful for people who may require larger amounts of inhaled medications, such as those for:

• acute asthma attacks
• pneumonia
• COPD

A doctor would usually prescribe nebulized medications to treat acute bronchitis in children or for chronic bronchitis in adults.

Examples of nebulized medications include:

• Long-acting beta-2 agonists (LABAs). These medications are usually the same as those available for inhalers.
• Long-acting muscarinic agents (LAMAs). These medications work on different receptors in the lungs than beta-agonists to help open up the airways so you can breathe better. Examples of these medicines include umeclinium (Ellipta) and tiotropium (HandiHaler, Respimat).
• Short-acting beta-agonists (SABAs). Like with traditional inhalers, a person can use albuterol in a nebulizer. These are mostly for acute attacks in bronchitis, such as wheezing.
• Short-acting muscarinic antagonists (SAMAs). These are medications like ipratropium bromide (Atrovent). Doctors prescribe them to treat chronic bronchitis and COPD.

Many of these medications are available in combination, such as SABA-SAMA or LABA-LAMA.

Nebulized medications may not be as good a fit for adults without COPD, because nebulizers require special equipment and teaching to use.

Ideally, a person with acute bronchitis wouldn’t need this type of equipment.

In addition to nebulizers and inhalers, some people may inhale warm, humidified air (steam) at home to improve their breathing.

Sometimes cold air can irritate the lungs and worsen coughing when you have bronchitis. Warm, moist air may help you feel better and reduce coughing.

Here are some ways you can incorporate steam or mist therapy into your bronchitis treatments:

• inhale steam from a bowl of boiling water, while hovering at least 8 to 12 inches away with a towel over your head to hold the steam in
• take a hot shower
• use a humidifier in your room, but be sure to carefully clean it after use

Many drugstores also sell plugin steam inhalers.

The side effects from inhalers and nebulizer treatments depend upon the type used. Examples of side effects include the following:

• Beta-2 agonists may cause tremors, nervousness, and shakiness.
• Corticosteroids can causesore mouth, cough, hoarse voice, or nosebleeds. Oral thrush can develop if a person doesn’t rinse their mouth out after use.
• LABAs can cause heart palpitations and tremors.
• LAMAs may cause constipation, dry mouth, and urinary retention.

If you experience any of these when you use an inhaler or nebulizer, talk to your doctor about ways to minimize these side effects. You can also find out if other medications are available.

They may suggest using a spacer device, which maximizes the delivery of the medication to the lungs. This minimizes the settling of medication to the back of the throat, which can lead to side effects.

With treatment and rest, you’ll ideally recover within about 1 to 2 weeks. It may take a bit longer for some people.

If your symptoms, especially your cough, persist beyond 3 weeks, consider scheduling another appointment with your doctor.

A doctor can evaluate you for other potential coughing causes, such as:

• asthma
• sinusitis
• COPD
• gastroesophageal reflux disease (GERD)
• heart failure
• pulmonary embolism

According to StatPearls, doctors may misdiagnose as many as one-third of patients with bronchitis when the patients actually have asthma.

You should talk with a doctor if you have a cough that persists after an upper respiratory infection, and it keeps you from completing everyday activities or starts to make your chest hurt.

If you have a fever that accompanies your symptoms, your infection may be bacterial. A doctor can prescribe antibiotics that can help bronchitis go away.

If your cough persists after 3 weeks, you may need to make another appointment with your doctor. Bronchitis will usually subside by this time, so you could have another medical condition.

Sometimes, bronchitis can lead to pneumonia. This is a severe lung infection.

Seek emergency medical treatment if you have worsening symptoms like:

• shortness of breath
• blue-tinted lips or fingernails
• confusion

Doctors usually treat bronchitis by treating its symptoms.

If your symptoms include wheezing and coughing, your doctor may prescribe an inhaler or nebulizer. These may help you manage your symptoms until you start feeling better.

Bronchitis

Bronchitis is an inflammation of the lower respiratory tract (bronchi), which carries air into the lungs. Inflammation causes swelling, narrowing of the lumen of the bronchi, increased sputum formation.

Distinguish between acute bronchitis and chronic obstructive pulmonary disease (COPD). They have a different mechanism of development, a different course, which requires, accordingly, a different approach to treatment.

Acute bronchitis is very common and is most often caused by viruses, rarely by bacteria, and even less often by fungal infection or toxins. The prognosis for acute bronchitis is favorable – almost all cases end in complete recovery. The illness usually lasts for about 10 days, although a person can cough for several more weeks.

COPD damages not only the bronchi, but also lung tissue. Pathological changes develop for a long time, are irreversible, significantly disrupt breathing and, as a result, the work of the whole organism. The main cause of COPD is smoking. The prognosis for COPD is generally unfavorable, but modern methods of treatment can alleviate the condition of patients with COPD.

Synonyms Russian

Acute bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, COPD, bronchiolitis, chronic lung disease, chronic obstructive pulmonary disease, COPD, chronic nonspecific lung disease

Synonyms English

Chronic bronchitis, bronchiolitis, chronic airway inflammation, COPD, chronic obstructive pulmonary disease, chronic bronchitis, chronic obstructive airway disease, COAD, chronic obstructive lung disease, COLD, acute bronchitis, chest cold.

Symptoms

The main symptoms of acute bronchitis and COPD are:

• cough,
• shortness of breath,
• chest tightness.

Acute bronchitis often occurs after SARS or influenza, so it may be accompanied by fever, weakness, malaise and other non-specific signs of infection. Cough in acute bronchitis lasts from 10 days to several weeks, in COPD – for 3 months a year for at least 2 years.

General information about the disease

The bronchi are breathing tubes through which air enters the lungs, while being moistened, cleansed and warmed. Their wall consists of several layers and contains cartilaginous rings, muscle fibers. From the inside, the bronchi are lined with a membrane covered with a layer of mucus, which is produced by goblet cells. Cleansing of the bronchi occurs due to the movement of the processes of the ciliated cells of the mucous membrane. After passing through the bronchi, the air enters the alveoli – the structural elements of the lung tissue, where gas exchange occurs.

In acute bronchitis, the bronchi are damaged by microbes and toxins, the cells of the mucous membrane are destroyed, as a result, the movement of cilia is disturbed, goblet cells and bronchial glands secrete a very large amount of mucus that stagnates, the lumen of the bronchi decreases, small bronchi can become blocked. The mucous membrane swells, becomes inflamed. All this leads to coughing, difficulty breathing. In acute bronchitis, these processes, as a rule, undergo a reverse change within three weeks.

The main cause of COPD is smoking, less often long-term exposure to dust containing cadmium, lead, silicon, organic dust, ammonia fumes, chlorine, hydrogen sulfide, phosgene and other toxic substances. In COPD, the symptoms of the disease occur already with significant structural changes in the lungs. Unlike acute bronchitis, not only the bronchi are damaged, but also the alveoli – their walls become thinner, collapse, become less elastic. The walls of the bronchioles are compressed, the walls of the bronchi thicken, deform, and airway obstruction occurs. COPD can lead to severe pulmonary and cardiovascular complications and is one of the leading causes of death worldwide.

Who is at risk?

• Smokers.
• Elderly people.
• Children.
• People who are immunosuppressed due to another acute or chronic illness.
• Those who often come into contact with chemicals and toxins at work (chemists, metallurgists, railway workers, miners).

Diagnosis

The diagnosis of bronchitis is based on the presence of relevant symptoms, medical examination, and the results of diagnostic procedures.

Laboratory diagnostics

• Complete blood count (without leukocyte formula and ESR) with leukocyte formula. In acute bronchitis, the number of leukocytes can be increased, mainly due to neutrophils. With COPD, there are usually no changes in the complete blood count.
• ESR – erythrocyte sedimentation rate. In acute bronchitis, it can be increased.
• C-reactive protein. May be elevated in acute bronchitis.
• General sputum analysis. Sputum examination is necessary to exclude a number of lung diseases: cancer, tuberculosis, pneumonia, etc.

Other research methods

• Chest X-ray. Used to rule out other lung conditions that can cause coughing, or complications of bronchitis such as pneumonia. In uncomplicated bronchitis, there are usually no changes on the radiograph. In COPD, the bronchi can become deformed.
• Bronchoscopy. It is carried out to examine the mucous membrane for the presence of deformations. To do this, use a special device – a bronchoscope. It consists of a flexible rod equipped with a video camera, a light and a manipulator for taking a sample of bronchial tissue, and allows direct examination of the bronchi.
• Spirometry. During the study, the patient takes a deep breath, and then quickly exhales into a special device – a spirometer. This test is done to look for signs of asthma or emphysema, in which there are signs of air retention in the lungs.

Treatment

Treatment of bronchitis depends on the cause that caused it, the type of bronchitis, the severity of the patient’s condition.

Acute bronchitis requires bed rest, plenty of warm drink, air humidification in the apartment. As a rule, it is successfully treated at home. Hospitalization is required only in severe cases or for young children. For the treatment of acute bronchitis, antibiotics are used (in the case of a bacterial nature of bronchitis), mucolytics (drugs that thin sputum), in some cases, antitussive drugs and bronchodilators (drugs that expand the lumen of the bronchi).

Treatment for COPD does not lead to a complete restoration of the patency and structure of the lungs – this disease is steadily progressing, despite therapy. However, it helps to reduce the main manifestations of the disease, slow down its development and allows the patient to lead a more active lifestyle.

COPD can be treated with glucocorticosteroids, oxygen therapy, possibly surgical treatment. Glucocorticosteroids are used during an exacerbation. When using steroids, remission (relief) is achieved faster and lasts longer. Oxygen therapy is the additional saturation of the patient’s blood with oxygen, usually with the help of a mask. Therapy for COPD should be continuous, include a complex of rehabilitation and general health procedures.

Prevention

To reduce the risk of bronchitis:

• stop smoking,
• observe the rules of hygiene,
• use protective equipment when working with toxic substances,
• to be vaccinated in a timely manner.

Recommended tests

• CBC
• Leukocyte formula
• ESR
• General sputum analysis
• C-reactive protein, quantitatively

Acute bronchitis – causes, diagnosis and treatment

• Home >

• About clinic >

• Events >

• Acute bronchitis

Each of us at least once a year suffers from colds, often accompanied by a cough. And it happens that on examination by a doctor, the patient is diagnosed with acute bronchitis. This often frightens the patient. Let’s deal with this “insidious” disease.

Bronchitis – is an inflammatory disease of the mucous membrane of the bronchi, the respiratory “tubules” leading to the alveoli (terminal gas exchange sections of the lungs). Some statistics. According to the World Health Organization, the incidence of acute bronchitis is approximately 30% per year. The disease is one of the ten most common reasons for seeking medical help. However, in Russia there are no clear standards for diagnosing acute bronchitis, which also often occurs under the guise of SARS. All this makes the problem of this disease very relevant.

Reasons for the appearance of

Most often inflammation of the bronchi is caused by viruses (influenza viruses, parainfluenza, rhinoviruses, coronaviruses). In recent years, cases of bronchitis caused by chlamydia, mycoplasma, whooping cough have become more frequent. In 10% of cases, the bronchi are affected by a bacterial infection. As a rule, this group includes children under 2 years old and adults over 60 years old. Often there is a joint action of various pathogens. However, do not forget about non-infectious agents of acute bronchitis (high and low air temperatures, chemical compounds, allergens).

Disease diagnosis

What is the clinical picture of acute bronchitis? The main symptom is a cough, often dry, although it can be with the separation of both mucous and mucopurulent sputum. Body temperature may be within normal limits or rise to 37.5*-38.0*. Shortness of breath, a feeling of congestion in the chest, “whistling” breathing appear when the small bronchi or bronchioles are affected and indicate the addition of bronchial obstruction. It should be taken into account the fact that cough may appear as a continuation of the course of SARS or as an independent and often the only symptom. When examining a patient, the doctor listens to dry rales of various timbres in the lungs. X-ray of the chest organs does not reveal changes in the lung tissue. In a clinical blood test, there may be no changes, or a moderate increase in the level of leukocytes, neutrophils, and monocytes is detected. Thus, the scarcity of symptoms and the disguise of the disease under SARS dictates the need for a mandatory medical examination by an experienced specialist in order to effectively counteract the disease.

Treatment features

At the height of the disease, the patient needs a home regimen, plentiful alkaline drinking, antitussive drugs for dry cough, mucolytics for wet cough, with the addition of bronchial obstruction – bronchodilators, often in the form of inhalations. It is quite justified to use antibiotics for ARVI in people over 55 years of age with frequent coughing, purulent sputum and severe intoxication.
Acute bronchitis, on average, lasts 7-10 days. Patients do not need hospitalization. The exception is patients with obstructive bronchitis and acute bronchiolitis.